Receptor imaging of human diseases using radiolabeled peptides
Related Experiment Videos
J C Reubi1, S J Lamberts, E P Krenning
1Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Switzerland.
Abstract:
The peptide somatostatin and its analog octreotide play an important role in neoplasia where their actions have been shown to be mediated by specific somatostatin receptors located in the tumor tissue. The identification of a high density of SS receptors in vitro in different types of human tumors has provided completely new and attractive possibilities for their diagnostic localization in vivo. This can be achieved by intravenous injection of 123I-[Tyr3]-octreotide or 111In-DTPA-D-Phe1-octreotide in patients suspected of having SS receptor-positive tumors and by subsequent localization of the tumors with gamma camera scintigraphy techniques. Hot spots representing radioligand binding on SS receptor-positive tumors are visualized with this method. This new SS receptor imaging method may help the clinicians for the localization of the primary tumor and its metastases, for the staging of certain tumors, to predict a successful SS therapy, and as a prognostic or differential diagnostic marker. It may also be of use in non-tumoral pathologies, to localize selected inflammatory processes and to monitor anti-inflammatory therapy. Somatostatin receptor imaging represents the first example of the clinical use of a small peptide as an efficient in vivo diagnostic tool and may be considered as a paradigm for further research on the role and the potential diagnostic use of other peptide receptors in pathological states.
Insights
Somatostatin receptor imaging uses radiolabeled peptides to detect tumors and inflammatory processes. This diagnostic tool aids in tumor localization, staging, and therapy prediction.
Area of Science:
- * Oncology and Nuclear Medicine
- * Peptide receptor imaging
Background:
- * Somatostatin and octreotide are peptides crucial in neoplasia, acting via somatostatin receptors (SSRs) in tumor tissues.
- * High in vitro density of SSRs in human tumors offers diagnostic potential.
- * SSRs are implicated in both neoplastic and non-neoplastic inflammatory conditions.
Purpose of the Study:
- * To evaluate the diagnostic utility of in vivo somatostatin receptor imaging.
- * To explore the application of peptide-based imaging for tumor and inflammation detection.
- * To establish peptide receptor imaging as a paradigm for diagnostic tools.
Main Methods:
- * Intravenous injection of radiolabeled octreotide analogs (e.g., 123I-[Tyr3]-octreotide, 111In-DTPA-D-Phe1-octreotide).
- * Localization of radioligand binding in vivo using gamma camera scintigraphy.
- * Visualization of "hot spots" indicating SSR-positive tissues.
Main Results:
- * Successful visualization of SSR-positive tumors and inflammatory processes.
- * Demonstration of peptide-based imaging as an effective diagnostic method.
- * Identification of "hot spots" correlating with SSR expression.
Conclusions:
- * Somatostatin receptor imaging is a valuable tool for localizing primary tumors and metastases.
- * This method aids in tumor staging, predicting therapy response, and differential diagnosis.
- * Peptide receptor imaging represents a novel in vivo diagnostic approach with broad clinical applications.